Cardiovascular Drugs and Therapy

, Volume 7, Issue 6, pp 893–896 | Cite as

Digoxin is effective, but is it safe?

  • Frank I. Marcus
Postinfarct Heart Failure: Invited Viewpoint


In the last 15 years several double-blind, placebo-controlled clinical trials have unequivocally shown that digitalis decreases symptoms of cardiac failure, results in a reduction in the need for hospitalization for treatment of congestive heart failure, and improves cardiac function. The major unresolved question concerning digitalis use is its safety. There are experimental data and clinical evidence that digitalis use may be associated with an increased mortality, particularly in the first year or two after an acute myocardial infarction. This increased mortality appears to be present even after adjustment for predictor covariants. This conclusion depends on the ability of statistical methods to account for differences in comorbidity. Since the question of digitalis safety remains after myocardial infarction, the physician should carefully examine the indications for administration of digitalis. More than the usual surveillance is required during chronic digitalis administration.

Key Words

digoxin digitalis digoxin efficacy digoxin safety post myocardial infarction independent risk factor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Whitfield HAW. Bicentary of “An Account of the Foxglove.” Historical address given at Edgbaston Parish Church, Birmingham.Br Heart J 1985;54:253–255.PubMedGoogle Scholar
  2. 2.
    Wood P. The action of digitalis in heart failure with normal rhythm.Br Heart J 1940;2:132–140.Google Scholar
  3. 3.
    Gavey CJ, Parkinson J. Digitalis in heart failure with normal rhythm.Br Heart J 1939;1:27–44.Google Scholar
  4. 4.
    Dobbs S, Kenyon W, Dobbs R. Maintenance digoxin after an episode of heart failure: Placebo-controlled trial in outpatients.Br Med J 1977;1:749–752.PubMedGoogle Scholar
  5. 5.
    Lee D, Johnson R, Bingham J, et al. Heart failure in outpatients: A randomized trial of digoxin versus placebo.N Engl J Med 1982;306:699–705.PubMedGoogle Scholar
  6. 6.
    Fleg J, Gottlieb S, Lakatta E. Is digoxin important in treatment of compensated heart failure?Am J Med 1982;73:244–250.PubMedGoogle Scholar
  7. 7.
    Taggart A, Johnston G, McDevitt D. Digoxin withdrawal after cardiac failure in patients with sinus rhythm.J Cardiovasc Pharmacol 1983;5:229–234.PubMedGoogle Scholar
  8. 8.
    Guyatt G, Sullivan M, Fallen E, et al. A controlled trial of digoxin in congestive heart failure.Am J Cardiol 1988;61:371–375.PubMedGoogle Scholar
  9. 9.
    German and Australian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure.Lancet 1988;1:489–493.Google Scholar
  10. 10.
    Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure.JAMA 1988;259:539–544.Google Scholar
  11. 11.
    DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.N Engl J Med 1989;320:677–683.PubMedGoogle Scholar
  12. 12.
    Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Bloomfield JG. Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long term treatment.Br Heart J 1989;61:529–539.PubMedGoogle Scholar
  13. 13.
    Fleg J, Rothfeld B, Gottlieb S. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: A randomized, placebo-controlled, crossover trial.J Am Coll Cardiol 1991;17:743–751.PubMedGoogle Scholar
  14. 14.
    Young JB, Uretsky BF, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. On behalf of the PROVED study investigators. Multicenter, double-blind, placebo-controlled randomized withdrawal trial of the efficacy and safety of digoxin in patients with mild to chronic heart failure not treated with converting enzyme inhibitors.J Am Coll Cardiol 1992;19:259.Google Scholar
  15. 15.
    Packer M, Gheorghiade M, Young JB, et al. Withdrawl of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE study.N Engl J Med 1993;329:1–7.PubMedGoogle Scholar
  16. 16.
    Drexler H, Schumacher M, Siegrist J, Just H., for the CADS Multicenter Study Group. Effect of captopril and digoxin on quality of life and clinical symptoms in patients with coronary artery disease and mild heart failure.J Am Coll Cardiol 1992;19:260.Google Scholar
  17. 17.
    Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure.J Am Coll Cardiol 1989;13:134–142.PubMedGoogle Scholar
  18. 18.
    Marcus FI. Digitalis. In: Hurst JW, Schlant RC, eds.The Heart, 7th ed. New York: McGraw Hill, 1990:1748–1761.Google Scholar
  19. 19.
    Lynch JJ, Montgomery DG, Lucchesi BR. Facilitation of lethal ventricular arrhythmias by therapeutic digoxin in conscious postinfarction dogs.Am Heart J 1986;111:883.PubMedGoogle Scholar
  20. 20.
    Lynch JJ, Kitzen JM, Hoff PT, Lucchesi BR. Reduction in digitalis associated post infarction mortality with nadalol in conscious dogs.Am Heart J 1988;115:67–76.PubMedGoogle Scholar
  21. 21.
    Moss AJ, Davis HT, Conard DL, DeCamilla JJ, Odoroff GL. Digitalis-associated cardiac mortality after myocardial infarction.Circulation 1981;64:1150–1155.PubMedGoogle Scholar
  22. 22.
    Bigger JT Jr, Fleiss JL, Rolnitzky LM, Merab JP, Ferrick KJ. Effects of digitalis treatment on survival after acute myocardial infarction.Am J Cardiol 1985;55:623–630.PubMedGoogle Scholar
  23. 23.
    The Digitalis Subcommittee of the Multicenter Post-Infarction Research Group. The mortality risk associated with digitalis treatment after myocardial infarction.Cardiovasc Drugs Ther 1987;1:125–132.Google Scholar
  24. 24.
    Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis—a new controversy regarding an old drug. The pitfalls of inappropriate methods.Circulation 1986;73:14–17.PubMedGoogle Scholar
  25. 25.
    Fleiss JL, Bigger JT, Rolnitzky LM. Is Catch-22 alive and well and living at NHLBI? Reactions to “Digitalis, a new controversy regarding an old drug.”Circulation 1986;73:119–20.Google Scholar
  26. 26.
    Sweeney MO, Moss AJ, Eberly S, Andrews M. Instantaneous cardiac death in the post-hospital period after acute myocardial infarction.Am J Cardiol 1992;70:1375–1379.PubMedGoogle Scholar
  27. 27.
    Molstad P, Abdelnoor M. Digitoxin-associated mortality in acute myocardial infarction.Eur Heart J 1991;12:65–69.Google Scholar
  28. 28.
    Ryan TJ, Bailey KR, McCabe CH, et al. The effect of digitalis on survival in high-risk patients with coronary artery disease.Circulation 1983;67:735–742.PubMedGoogle Scholar
  29. 29.
    Madsen EB, Gilpin E, Henning H, et al. Prognostic importance of digitalis after acute myocardial infarction.J Am Coll Cardiol 1984;3:681–689.PubMedGoogle Scholar
  30. 30.
    Muller J, Turi Z, Stone PH, et al. and the MILIS Study Group. Digoxin therapy and mortality after myocardial infarction: Experience in the MILIS Study.N Engl J Med 1986;314:265–271.PubMedGoogle Scholar
  31. 31.
    Byington R, Goldstein S. For the BHAT Research Group. Association of digitalis therapy with mortality in survivors of acute myocardial infarction: Observations in the Beta-Blocker Heart Attack Trial.J Am Coll Cardiol 1985;6:976–982.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Frank I. Marcus
    • 1
  1. 1.University of Arizona College of MedicineTucson

Personalised recommendations